Axsome Therapeutics Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-51.3M | $-64.5M | $-47.2M | $-48.0M | $-59.4M | $-64.6M | $-79.3M | $-68.4M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | $116.0K | — | — | $149.0K | — | — | $132.0K |
| Amortization | $1.6M | $1.6M | $1.6M | $1.6M | $1.6M | $1.6M | $1.6M | $1.6M |
| Stock-Based Compensation | $27.1M | $23.4M | $23.1M | $24.6M | $23.3M | $21.7M | $21.4M | $20.2M |
| Net Cash from Operating Activities | $-33.0M | $-20.7M | $1.0M | $-32.4M | $-43.4M | $-18.6M | $-30.1M | $-53.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $450.0K | $121.0K | $58.0K | $13.0K | $338.0K | $90.0K | $52.0K | $98.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-121.0K | — | — | $-338.0K | — | — | $-98.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $3.0M | — | — | $29.3M | — | — | $-1.2M |
| Net Change in Cash | — | $-17.8M | — | — | $-14.4M | — | — | $-54.8M |
| Free Cash Flow | $-33.4M | $-20.8M | $988.0K | $-32.4M | $-43.7M | $-18.7M | $-30.2M | $-53.6M |